Fig 1: S100A9 blockade improves neuronal cell survival after SCI. Immunofluorescence of (A) MAP2 and (B) NF200 at the lesion site on day 28 following surgery among the different experimental groups. (C) Nissl staining for neuronal morphology at the lesion site 28 days post-OR among groups. n=5. Scale bar, 200 µm. **P<0.01, ***P<0.001. ##P<0.01. S100A9, S100 calcium-binding protein A9; SCI, spinal cord injury; MAP2, microtubule associated protein 2; NF200, neurofilament 200; post-OR, after the operation; High-ABR, high ABR dose; Low-ABR, low ABR dose.
Fig 2: H&E staining was used to detect possible pathological damage caused by S100A9 in tissues and organs. Scale bar, 500 µm. S100A9, S100 calcium-binding protein A9; SCI, spinal cord injury; High-ABR, high ABR dose; Low-ABR, low ABR dose.
Fig 3: S100A9 expression in the spinal cord tissue and serum following SCI. S100A9 (A) mRNA and (B) protein expression level, and (C) concentration in the spinal cord tissue and serum from the SCI and Sham groups pre-OR and at 3, 6, 12, 24, 48 and 72 h post-OR, respectively. (D) Correlation analysis between S100A9 and IL-1ß, IL-6, TNF-a, IL-4 and IL-10 concentration using Pearson's correlation analysis. Data are presented as the mean ± SD. n=5. ***P<0.001 vs. Sham group; ###P<0.001 vs. Before-SUR group. S100A9, S100 calcium-binding protein A9; SCI, spinal cord injury; pre-OR, before the operation; post-OR, after the operation.
Fig 4: S100A9 blockade improves the recovery of the injured cord after SCI. (A) H&E staining for histological analysis 28 days post-OR among the different experimental groups. Scale bar, 1 mm (upper panel) and 200 µm (lower panel). (B) Relative cavity sizes were calculated by dividing the cavity volume by the spinal cord volume at the lesion site in the vertical direction. (C) BBB score evaluation for motor function after SCI among the different experimental groups. Data are presented as the mean ± SD. n=5. *P<0.05, ***P<0.001. #P<0.05. S100A9, S100 calcium-binding protein A9; SCI, spinal cord injury; post-OR, after the operation; BBB, Basso-Beattie-Bresnahan; High-ABR, high ABR dose; Low-ABR, low ABR dose; n.s., not significant.
Fig 5: S100A9 blockade relieves inflammation and apoptosis after SCI. (A) Immunohistochemistry for MPO at the lesion site 28 days post-OR among groups. (B) mRNA expression level of pro-inflammatory genes (IL-1ß, IL-6 and TNF-a) and anti-inflammatory genes (IL-4 and IL-10) at the injury site 28 days post-OR among the groups. (C) Protein expression level of Bcl2, Bax and cleaved caspase-3 at the injury site 28 days post-OR among the groups. n=5. ***P<0.001. #P<0.05, ###P<0.001. Scale bar, 200 µm. S100A9, S100 calcium-binding protein A9; SCI, spinal cord injury; MPO, myeloperoxidase; post-OR, after the operation; High-ABR, high ABR dose; Low-ABR, low ABR dose; n.s, not significant.
Supplier Page from Wuhan Fine Biotech Co., Ltd. for Recombinant Rat S100A9